Merck is developing molnupiravir along with Ridgeback Biotherapeutics. Credit: Copyright © Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA All rights reserved.

Merck (MSD) and the Medicines Patent Pool (MPP) have entered a voluntary licencing agreement to offer affordable international access for the former’s experimental oral antiviral, molnupiravir (MK-4482/EIDD-2801), to treat Covid-19.

Invented at Emory University and licenced to Ridgeback Biotherapeutics, molnupiravir is an orally administered potent ribonucleoside analogue that can prevent the SARS-CoV-2 virus replication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug is currently being developed by Merck in partnership with Ridgeback Biotherapeutics.

It is intended to treat mild-to-moderate Covid-19 in adult patients at risk of the disease progressing to severity and/or hospitalisation.

With the latest deal, MPP will be able to provide non-exclusive sublicenses to manufacturers and expand the production base for the distribution of molnupiravir to various nations.

Following necessary regulatory clearances, the alliance will offer expanded access to usage of the antiviral in 105 low- and middle-income countries.

As long as Covid-19 is considered as a Public Health Emergency of International Concern by the World Health Organization (WHO), Merck, Ridgeback and Emory University will not be eligible for royalty payments for molnupiravir sales.

Merck Human Health executive vice-president and president Frank Clyburn said: “This agreement with MPP is another important element in our multi-faceted strategy to accelerate broad, affordable access to molnupiravir, if approved or authorized, for patients no matter where they live, including in countries where governments face greater challenges to finance healthcare.”

Earlier this month, Merck and Ridgeback submitted an emergency use authorization (EUA) application to the US Food and Drug Administration for molnupiravir.

The companies are also pursuing authorisation from various other regulatory authorities across the globe.

Furthermore, the European Medicines Agency (EMA) has commenced a rolling review for the drug to treat Covid-19 in adult patients.